These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36878410)

  • 41. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
    Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
    Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of intraosteoblastic activity of dalbavancin against Staphylococcus aureus in an ex vivo model of bone cell infection.
    Chauvelot P; Dupieux-Chabert C; Abad L; Souche A; Ferry T; Josse J; Laurent F; Valour F;
    J Antimicrob Chemother; 2021 Oct; 76(11):2863-2866. PubMed ID: 34423360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
    Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
    Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study.
    Pascale R; Maccaro A; Mikus E; Baldassarre M; Tazza B; Esposito F; Rinaldi M; Tenti E; Ambretti S; Albertini A; Viale P; Giannella M; Bartoletti M
    J Glob Antimicrob Resist; 2022 Sep; 30():390-394. PubMed ID: 35878780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.
    Bradley JS; Puttagunta S; Rubino CM; Blumer JL; Dunne M; Sullivan JE
    Pediatr Infect Dis J; 2015 Jul; 34(7):748-52. PubMed ID: 25551831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections.
    Doub JB; Alkayali T; Amoroso A; Nandi S; Talwani R
    Eur J Orthop Surg Traumatol; 2023 Dec; 33(8):3655-3659. PubMed ID: 37270761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
    Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
    Trials; 2022 May; 23(1):407. PubMed ID: 35578360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
    Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.
    Matesanz M; Poza A; Iñurrieta A; Fernández-Diaz E; Arroyo M; Domínguez I; Candel FJ
    Rev Esp Quimioter; 2021 Aug; 34(4):396-399. PubMed ID: 33956412
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant
    Gatti M; Giannella M; Rinaldi M; Gaibani P; Viale P; Pea F
    Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
    Soriano A; Rossolini GM; Pea F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
    [No Abstract]   [Full Text] [Related]  

  • 56. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
    Valerio M; Veintimilla C; Rodríguez C; de la Villa S; Sánchez-Somolinos M; Cerezales M; Crespo C; Rodríguez S; Adán I; Chamorro E; Rosselló I; Muñoz P
    J Med Econ; 2023; 26(1):463-472. PubMed ID: 36950932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU.
    Ritchie H; Aggarwal A; Schimmel J; Lorenzo MP
    J Infect Chemother; 2022 Mar; 28(3):465-468. PubMed ID: 35016828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A HPLC-DAD method to facilitate large-scale therapeutic drug monitoring of dalbavancin.
    Destere A; Merino D; Bonesso L; Lavrut T; Bernasconni A; Garraffo R; Gérard AO; Drici MD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1222():123694. PubMed ID: 37060815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
    Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
    Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.